Considering that the natural tumor growth kinetics might significantly impact the tumor microenvironment, we hypothesized that pre-treatment TGR could predict PFS of aNSCLC patients undergoing anti-PD-1/PD-L1 immunotherapy. Here, PDCD1 is linked to neoplasm.